Overview
TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, TCG Crossover Fund III, L.P., and TCG Crossover GP III, LLC reported purchases of Surrozen, Inc. (NASDAQ: SRZN) common stock in transactions that took place between January 30 and February 3, 2026. The combined value of those purchases totaled $202,534. Reported execution prices for the acquisitions ranged from $21.38 to $21.94 per share.
Transaction details
The filings show a concentrated buying window spanning five calendar days. The four named TCG entities are listed as the purchasers; each transaction involved Surrozen common stock. The aggregate consideration for the shares was $202,534, with individual trade prices falling within the $21.38 to $21.94 range.
Board change
In a separate disclosure filed with the SEC, Surrozen announced that Shao-Lee Lin, M.D., Ph.D., resigned from its Board of Directors, effective immediately. The company noted that Dr. Lin's resignation was not the result of any disagreement with Surrozen regarding the company's operations, policies, or practices. The filing records the company's appreciation for Dr. Lin's service and dedication during her tenure, and does not indicate any replacement or additional board changes at this time.
Context and immediate takeaway
The registrants' purchases and the board resignation are presented as distinct developments in the company's recent disclosures. The filings provide specific dollar amounts, trade price ranges, and a clear statement regarding the nature of the board member's departure. Beyond these items, the filings do not supply further commentary, replacement plans, or additional corporate governance changes.
Conclusion
The recent activity reported in public filings consists of a set of institutional purchases totaling $202,534 executed at prices between $21.38 and $21.94, alongside the immediate resignation of a board member who left without publicly stated disagreement with company practices. No further details on board succession or additional insider activity were provided in the referenced disclosures.